支气管哮喘患者炎性因子水平与气道重构关系探讨  

The Relationship between Inflammatory Cytokine Levels and Airway Remodeling in Patients with Bronchial Asthma

作　　者：师国强 丁晨光[2] 

机构地区：[1]洛阳市第一人民医院呼吸科,河南洛阳471002 [2]西安交通大学医学部第一附属医院,陕西西安710061

出　　处：《昆明医科大学学报》2014年第8期86-88,102,共4页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(81102247)

摘　　要：目的探讨支气管哮喘患者炎性因子水平与气道重构水平并进行相关性分析.方法选择支气管哮喘患者106例,分为发作期组及稳定期组.分别有61例、45例,同时选择同期健康体检者40例为对照组,分别检测三组IL-2、IL-5、VEGF、bFGF、TGF-β1水平.结果稳定期组VEGF、bFGF、TGF-β1较对照组差异有统计学意义(P<0.05),发作期组VEGF、bFGF、TGF-β1较对照组及稳定期组差异有统计学意义(P<0.05).稳定期组IL-5较对照组差异有统计学意义(P<0.05),发作期组IL-2、IL-5较对照组及稳定期组差异有统计学意义(P<0.05).IL-2与TGF-β1有相关性(P<0.05),IL-5与VEGF、bFGF、TGF-β1有相关性(P<0.05).结论支气管哮喘患者炎性因子水平失调与VEGF、bFGF、TGF-β1导致的气道纤维化密切相关,2种因素共同导致支气管哮喘进展.Objective To investigate the relationship between inflammatory cytokine levels and airway remodeling in bronchial asthma patients.Methods 106 patients with bronchial asthma were divided into exacerbation group and stable groups,there were 61 cases,45 cases,separately,40 cases of healthy people were selected as control group.IL-2,IL-5,VEGF,bFGF,TGF-β 1 levels were detected.Results Compared with the control group,the levels of VEGF,bFGF,TGF-β 1 in stable group were significantly increased （P ＜ 0.05） Compared with the control group and the stable group,the levels of VEGF,bFGF,TGF-β 1 in exacerbation group were significantly increased （P ＜0.05）.The levels of IL-5 in stable group patients were significantly higher than the control group （P＜0.05）.The levels of IL-2 and IL-5 in exacerbation group patients were significantly higher than than those in the control group and the stable group patients （P＜0.05）.IL-2 and TGF-β 1 showed a significant positive correlation （P＜0.05）,IL-5 and VEGF,bFGF,and TGF-β 1 showed significant positive correlation （P＜0.05）.Conclusion The imbalance of inflammatory cytokine levels is closely related to airway fibrosis induced by VEGF,bFGF and TGF-β 1 in bronchial asthma patients,these two factors work together to lead to bronchial asthma progress.

关 键 词：支气管哮喘 炎性因子 气道重构 

分 类 号：R562.25[医药卫生—呼吸系统]